191 related articles for article (PubMed ID: 37291428)
81. Organ sparing management in rectal cancer. Are we there yet?
Andras D; Crisan D; Avram L; Caziuc A; Bintintan V; Coman RT; Portik D; Ionescu B; Hopartan C; Crisan N; Eniu D; Coman I; Dindelegan G
Ann Ital Chir; 2019; 90():532-538. PubMed ID: 31355776
[TBL] [Abstract][Full Text] [Related]
82. Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Morikawa T; Fukayama M; Watanabe T
Dis Colon Rectum; 2017 Apr; 60(4):368-375. PubMed ID: 28267003
[TBL] [Abstract][Full Text] [Related]
83. Watch-and-wait strategy in rectal cancer: Is there a tumour size limit? Results from two pooled prospective studies.
Jankowski M; Pietrzak L; Rupiński M; Michalski W; Hołdakowska A; Paciorek K; Rutkowski A; Olesiński T; Cencelewicz A; Szczepkowski M; Zegarski W; Reszke J; Richter P; Wawok P; Małecki K; Bębenek M; Szelachowska J; Mazurek M; Gisterek I; Polkowski W; Jankiewicz M; Styliński R; Socha J; Bujko K;
Radiother Oncol; 2021 Jul; 160():229-235. PubMed ID: 34023328
[TBL] [Abstract][Full Text] [Related]
84. [A prediction model of pathological complete response in patients with locally advanced rectal cancer after PD-1 antibody combined with total neoadjuvant chemoradiotherapy based on MRI radiomics].
Zhang XY; Zhu HT; Li XT; Li YJ; Li ZW; Wang WH; Wu AW; Sun YS; Zhang L
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):228-234. PubMed ID: 35340172
[No Abstract] [Full Text] [Related]
85. A Dynamic Clinical Calculator for Estimating Conditional Recurrence-Free Survival After Total Neoadjuvant Therapy for Rectal Cancer and Either Surgery or Watch-and-Wait Management.
Weiser MR; Chou JF; Kim JK; Widmar M; Wei IH; Pappou EP; Smith JJ; Nash GM; Paty PB; Cercek A; Saltz LB; Romesser PB; Crane CH; Garcia-Aguilar J; Schrag D; Gönen M
JAMA Netw Open; 2022 Sep; 5(9):e2233859. PubMed ID: 36173634
[TBL] [Abstract][Full Text] [Related]
86. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study.
van der Valk MJM; Hilling DE; Bastiaannet E; Meershoek-Klein Kranenbarg E; Beets GL; Figueiredo NL; Habr-Gama A; Perez RO; Renehan AG; van de Velde CJH;
Lancet; 2018 Jun; 391(10139):2537-2545. PubMed ID: 29976470
[TBL] [Abstract][Full Text] [Related]
87. Split scar sign to predict complete response in rectal cancer after neoadjuvant chemoradiotherapy: systematic review and meta-analysis.
Torri GB; Wiethan CP; Langer FW; de Oliveira GS; Meirelles AVB; Horvat N; Tse JR; Dias AB; Altmayer S
Eur Radiol; 2024 Jun; 34(6):3874-3881. PubMed ID: 37979009
[TBL] [Abstract][Full Text] [Related]
88. [Diagnosis and treatment strategy for clinical complete responders after chemoradiotherapy for rectal cancer: is watch-and-wait policy safe?].
Yao HW; Liu YH
Zhonghua Wai Ke Za Zhi; 2017 Jul; 55(7):496-499. PubMed ID: 28655076
[TBL] [Abstract][Full Text] [Related]
89. Efficacy and safety of wait and see strategy versus radical surgery and local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy: a meta-analysis.
Zhao GH; Deng L; Ye DM; Wang WH; Yan Y; Yu T
World J Surg Oncol; 2020 Aug; 18(1):232. PubMed ID: 32862826
[TBL] [Abstract][Full Text] [Related]
90. Nonoperative management after neoadjuvant therapy for rectal cancer: A single institution experience over 5 years.
Strode M; Shah R; Boland PM; Francescutti VA; Mangieri CW; Attwood K; Nurkin SJ
Surg Oncol; 2019 Mar; 28():116-120. PubMed ID: 30851884
[TBL] [Abstract][Full Text] [Related]
91. Diagnostic accuracy of b800 and b1500 DWI-MRI of the pelvis to detect residual rectal adenocarcinoma: a multi-reader study.
Bates DDB; Golia Pernicka JS; Fuqua JL; Paroder V; Petkovska I; Zheng J; Capanu M; Schilsky J; Gollub MJ
Abdom Radiol (NY); 2020 Feb; 45(2):293-300. PubMed ID: 31690966
[TBL] [Abstract][Full Text] [Related]
92. Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study.
Barina A; De Paoli A; Delrio P; Guerrieri M; Muratore A; Bianco F; Vespa D; Asteria C; Morpurgo E; Restivo A; Coco C; Pace U; Belluco C; Aschele C; Lonardi S; Valentini V; Mantello G; Maretto I; Del Bianco P; Perin A; Pucciarelli S
Tech Coloproctol; 2017 Aug; 21(8):633-640. PubMed ID: 28755256
[TBL] [Abstract][Full Text] [Related]
93. [Thoughts on the watch and wait strategy of patients with rectal cancer after neoadjuvant therapy].
Wen RB; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):230-236. PubMed ID: 32192300
[TBL] [Abstract][Full Text] [Related]
94. Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer.
Coraglio MF; Eleta MA; Kujaruk MR; Oviedo JH; Roca EL; Masciangioli GA; Mendez G; Iseas IS
World J Surg Oncol; 2020 Nov; 18(1):313. PubMed ID: 33256819
[TBL] [Abstract][Full Text] [Related]
95. A meta-analysis of the watch-and-wait strategy versus total mesorectal excision for rectal cancer exhibiting complete clinical response after neoadjuvant chemoradiotherapy.
Yu G; Lu W; Jiao Z; Qiao J; Ma S; Liu X
World J Surg Oncol; 2021 Oct; 19(1):305. PubMed ID: 34663341
[TBL] [Abstract][Full Text] [Related]
96. Nonoperative Management of Rectal Cancer: The Watch and Wait Strategy.
Vailati BB; São Julião GP; Habr-Gama A; Perez RO
Surg Oncol Clin N Am; 2022 Apr; 31(2):171-182. PubMed ID: 35351272
[TBL] [Abstract][Full Text] [Related]
97. Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
Habr-Gama A; Lynn PB; Jorge JM; São Julião GP; Proscurshim I; Gama-Rodrigues J; Fernandez LM; Perez RO
Dis Colon Rectum; 2016 Apr; 59(4):264-9. PubMed ID: 26953984
[TBL] [Abstract][Full Text] [Related]
98. Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.
Thompson HM; Omer DM; Lin S; Kim JK; Yuval JB; Verheij FS; Qin LX; Gollub MJ; Wu AJ; Lee M; Patil S; Hezel AF; Marcet JE; Cataldo PA; Polite BN; Herzig DO; Liska D; Oommen S; Friel CM; Ternent CA; Coveler AL; Hunt SR; Garcia-Aguilar J;
JAMA Netw Open; 2024 Jan; 7(1):e2350903. PubMed ID: 38194231
[TBL] [Abstract][Full Text] [Related]
99. Comparing outcomes and cost in surgery versus watch & wait surveillance of patients with rectal cancer post neoadjuvant long course chemoradiotherapy.
Crean R; Glyn T; McCombie A; Frizelle F
ANZ J Surg; 2024 Jun; 94(6):1151-1160. PubMed ID: 38486505
[TBL] [Abstract][Full Text] [Related]
100. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
